PURPOSE: To identify risk factors for chemotherapy-related nausea. METHODS: We examined risk factors for nausea in 1,696 patients from three multicenter studies conducted from 1998 to 2004. All patients were beginning a chemotherapy regimen containing cisplatin, carboplatin, or doxorubicin. Nausea was assessed on a 1-7 scale four times a day for 4 days by diary. RESULTS: First, average nausea for breast cancer patients receiving doxorubicin (mean = 2.31) was significantly greater than for other patients receiving doxorubicin (mean = 1.82), patients receiving cisplatin (mean = 1.88), and patients receiving carboplatin (mean = 1.45), Ps < 0.01. Second, mean nausea decreased steadily with age, P < 0.0001. Third, patients rating themselves more susceptible to nausea had significantly more nausea (adjusted mean = 2.51) than patients rating themselves less susceptible (adjusted mean = 1.92) and were 2.8 times more likely to experience severe nausea, Ps < 0.0001. Fourth, expected nausea was a significant predictor of average nausea, P = 0.034, but not severe nausea, P = 0.31. Last, no evidence that gender is a significant predictor of nausea in 299 patients with gender neutral cancers, P = 0.35. CONCLUSIONS: Specific patient characteristics, especially younger age and perceived susceptibility to nausea, can help clinicians in the early identification of patients who are more susceptible to treatment-related nausea.
PURPOSE: To identify risk factors for chemotherapy-related nausea. METHODS: We examined risk factors for nausea in 1,696 patients from three multicenter studies conducted from 1998 to 2004. All patients were beginning a chemotherapy regimen containing cisplatin, carboplatin, or doxorubicin. Nausea was assessed on a 1-7 scale four times a day for 4 days by diary. RESULTS: First, average nausea for breast cancerpatients receiving doxorubicin (mean = 2.31) was significantly greater than for other patients receiving doxorubicin (mean = 1.82), patients receiving cisplatin (mean = 1.88), and patients receiving carboplatin (mean = 1.45), Ps < 0.01. Second, mean nausea decreased steadily with age, P < 0.0001. Third, patients rating themselves more susceptible to nausea had significantly more nausea (adjusted mean = 2.51) than patients rating themselves less susceptible (adjusted mean = 1.92) and were 2.8 times more likely to experience severe nausea, Ps < 0.0001. Fourth, expected nausea was a significant predictor of average nausea, P = 0.034, but not severe nausea, P = 0.31. Last, no evidence that gender is a significant predictor of nausea in 299 patients with gender neutral cancers, P = 0.35. CONCLUSIONS: Specific patient characteristics, especially younger age and perceived susceptibility to nausea, can help clinicians in the early identification of patients who are more susceptible to treatment-related nausea.
Authors: Joseph A Roscoe; Pascal Jean-Pierre; Abhay R Shelke; Maralyn E Kaufman; Christopher Bole; Gary R Morrow Journal: Curr Probl Cancer Date: 2006 Mar-Apr Impact factor: 3.187
Authors: Jane T Hickok; Joseph A Roscoe; Gary R Morrow; Christopher W Bole; Hongwei Zhao; Karen L Hoelzer; Shaker R Dakhil; Timothy Moore; Tom R Fitch Journal: Lancet Oncol Date: 2005-09-13 Impact factor: 41.316
Authors: P J Hesketh; S M Grunberg; J Herrstedt; R de Wit; R J Gralla; A D Carides; A Taylor; J K Evans; K J Horgan Journal: Support Care Cancer Date: 2006-02-01 Impact factor: 3.603
Authors: Gary R Morrow; Lee Schwartzberg; Sally Y Barbour; Gianluca Ballinari; Michael D Thorn; David Cox Journal: J Community Support Oncol Date: 2014-07
Authors: Steven M Grunberg; David Warr; Richard J Gralla; Bernardo L Rapoport; Paul J Hesketh; Karin Jordan; Birgitte T Espersen Journal: Support Care Cancer Date: 2010-10-24 Impact factor: 3.603
Authors: Julie L Ryan; Charles E Heckler; Joseph A Roscoe; Shaker R Dakhil; Jeffrey Kirshner; Patrick J Flynn; Jane T Hickok; Gary R Morrow Journal: Support Care Cancer Date: 2011-08-05 Impact factor: 3.603
Authors: Anita R Peoples; Eva Culakova; Charles E Heckler; Michelle Shayne; Tracey L O'Connor; Jeffrey J Kirshner; Peter W Bushunow; Gary R Morrow; Joseph A Roscoe Journal: Support Care Cancer Date: 2019-03-30 Impact factor: 3.603
Authors: Thomas Kutner; Emily Kunkel; Yue Wang; Kyle George; Erik L Zeger; Zonera A Ali; George C Prendergast; Paul B Gilman; U Margaretha Wallon Journal: Support Care Cancer Date: 2016-10-12 Impact factor: 3.603
Authors: Karen M Mustian; Katie Devine; Julie L Ryan; Michelle C Janelsins; Lisa K Sprod; Luke J Peppone; Grace D Candelario; Supriya G Mohile; Gary R Morrow Journal: US Oncol Hematol Date: 2011